Navigation Links
Onconova to present clinical trials update on ON 01910.Na at American Society of Hematology Meeting
Date:12/3/2010

NEWTOWN, PA and PRINCETON, NJ Dec. 3, 2010 / PRNewswire-FirstCall / Onconova Therapeutics announces its late-stage anticancer agent, Estybon (ON 01910.Na), will be featured in three presentations at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, FL, December 4-7, 2010.

Principal investigators at four centers, Dr. Lewis Silverman (Mount Sinai Medical Center), Dr. Azra Raza (Columbia University Medical Center), Dr. Elaine Sloand (NHLBI), and Dr. Peter Greenberg (Stanford University Medical Center) report that in 48 higher risk patients with MDS or AML (who failed or became resistant to previous drug treatments), when treated with ON 01910.Na showed increases in overall survival, which correlated with bone marrow blast responses. The most dramatic improvement in overall survival was seen in 19 patients who also showed either bone marrow complete response (CR) or initial >50% decrease in blast cells (Abstract #3998). Dr. Greenberg's team reports encouraging efficacy and drug tolerance results in a Phase II trial with patients who had all failed the standard hypomethylating agent treatments (Abstract #4010). Dr. Silverman and colleagues have observed 50% responders in a Phase I study (Abstract #2944).

Estybon (ON 01910.Na) is a small molecule, targeted therapeutic with a broad spectrum of activity. It has been tested in patients with solid tumors, myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) at major centers in the U.S. and abroad. MDS and AML are blood disorders widely recognized as difficult to manage, with limited therapeutic options for patients, especially those with drug-resistant disease. The presentations will describe the latest results on activity and safety of Estybon (ON 01910.Na) in MDS and AML patients treated in on-going Phase I and Phase II clinical trials.

These studies are a part of comprehensive evaluation of the safety and activity of Estybon (ON 01910.Na). To date, nearly 300 cancer patients have been treated in Phase I and Phase II trials, including more than 70 patients with MDS or AML. These studies have lead to a multi-site Phase III pivotal trial under a Special Protocol Assessment (SPA) from the U.S. FDA. This trial is being supported by an award from the Therapeutics Acceleration Program (TAP) of the Leukemia and Lymphoma Society (LLS).

"We continue to make meaningful progress in our MDS program, and information to be presented at the ASH meeting reflects the breadth of data becoming available for ON 01910.Na in MDS patients," said Francois Wilhelm, MD, PhD, Senior Vice President and Chief Medical Officer of Onconova. "We are committed to the rapid development of this promising agent for MDS patients by conducting a multi-site trial in the United States and France," Dr. Wilhelm added.

Another presentation will highlight the mechanism of action and activity in nonclinical models of mantle cell lymphoma (MCL) of ON 013105, a novel Onconova agent directed to controlling Cyclin D1 in cancer cells (Abstract #771). ON 013105 alone or in combination with rituximab induced dramatic reduction of MCL tumor volumes in mouse xenograft models, suggesting that ON 013105 alone or in combination may be a potent therapeutic agent against MCL. ON 013105 is currently in Phase I clinical safety studies in lymphoma patients.


'/>"/>

Contact: Kathryn Morris
kathryn@proncall.com
845-635-9828
PR on Call
Source:Eurekalert

Related medicine news :

1. Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting
2. Connor Sport Court Lays the Ground for NBA All-Star Jam Session Presented by Adidas
3. FAB-HOMES™ Presents First Passive House Collection
4. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
5. Digital Signatures Presented at Electronic Document Management Conference
6. Compex , Leaders in Electronic Muscle Stimulators, Sponsors the Jelly Belly Cycling Team Presented by Kenda
7. Game Ready(R) Presented with Frost & Sullivan 2010 Product Differentiation Excellence Award
8. Great Salt Lake Chapter of National Contract Management Association Hosts Presentation on False Claims Act by Qui Tam Attorney Tim Terry
9. NOVAVAX Presents Positive Clinical Results at The World Health Organization Conference, Geneva, Switzerland
10. AADR presents honorary membership to Senator Tom Harkin
11. WebMD to Present at the Goldman Sachs Technology and Internet Conference 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology: